Articles By Mrinalini Dey, MD

lupus.nephritis.immunofluorescence.jpg

El obinutuzumab induce la remisión histológica en la nefritis lúpica

By Mrinalini Dey, MD

En el EULAR 2026, los investigadores presentan quizás los datos más convincentes desde el punto de vista biológico hasta la fecha del ensayo REGENCY, con evidencia de que el obinutuzumab induce una depleción profunda de células B intrarrenales junto con tasas notablemente más altas de remisión histológica.

Read Article
lupus.nephritis.immunofluorescence.jpg

Obinutuzumab drives histologic remission in lupus nephritis

By Mrinalini Dey, MD

At EULAR 2026, investigators are presenting perhaps the most biologically compelling data yet from the REGENCY trial, with evidence that obinutuzumab induces deep intrarenal B-cell depletion alongside markedly higher rates of histological remission.

Read Article
abstract

Nuevos inhibidores de la JAK en el panorama del tratamiento de la espondiloartritis axial (axSpA)

By Mrinalini Dey, MD

En EULAR 2026, dos grandes estudios de fase 3 destacan que la historia de los inhibidores de la JAK en la espondiloartritis axial (axSpA) sigue evolucionando rápidamente, con diferentes perfiles de selectividad y programas de desarrollo globales en expansión que continúan impulsando el campo.

Read Article
abstract

New JAK inhibitors in the axSpA treatment landscape

By Mrinalini Dey, MD

At EULAR 2026, two large phase 3 studies highlight that the JAK story in axSpA is still evolving rapidly, with different selectivity profiles and expanding global development programs continuing to push the field forward.

Read Article
Lung.Pleural.inflamm.AI

EPI-AR: detección de riesgos y susceptibilidad genética

By Mrinalini Dey, MD

La EPI-AR sigue siendo una de las manifestaciones extraarticulares más graves de la AR, contribuyendo sustancialmente a la morbilidad y la mortalidad. Dos resúmenes presentados en EULAR 2026 aportan importantes conocimientos para identificar a los pacientes con riesgo de EPI-AR y comprender los mecanismos genéticos que pueden sustentar el desarrollo de la enfermedad.

Read Article
Lung.Pleural.inflamm.AI

RA-ILD: Screening risk and genetic susceptibility

By Mrinalini Dey, MD

RA-ILD remains one of the most serious extra-articular manifestations of RA, contributing substantially to morbidity and mortality. Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development.

Read Article
safety data

JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal

By Mrinalini Dey, MD

Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings.

Read Article
safety data

Continúa el debate sobre la seguridad de los inhibidores de la JAK: una señal más fuerte de TEV y una señal menos clara de cáncer

By Mrinalini Dey, MD

Pocos temas en reumatología han remodelado el comportamiento prescriptor de forma tan drástica como las preocupaciones de seguridad en torno a los inhibidores de JAK tras el estudio ORAL Surveillance y las advertencias posteriores de la FDA y la EMA.

Read Article
safety data

Upadacitinib: revisiting safety data in RA and GCA

By Mrinalini Dey, MD

For the last several years, conversations about JAK inhibitors have often started and ended with safety. The shadow cast by ORAL Surveillance has made clinicians more cautious and regulators more restrictive.

Read Article
microbiome,blue

Microbiome may hold key to methotrexate response in RA

By Mrinalini Dey, MD

Methotrexate (MTX) remains the cornerstone of rheumatoid arthritis (RA) treatment, yet it remains unclear as to how to predict who will respond to it. Two studies presented at ACR (Abstracts 2639 and 2643) suggest the answer may be hiding in the gut.

Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Profile picture for user Mrinalini Dey, MD
  • Mrinalini Dey, MD

  • Dr. Mrinalini Dey is a Clinical Research Fellow at the Centre for Rheumatic Diseases, King’s College London, UK. She is also a Fellow-In-Training in Rheumatology and General Internal Medicine.  She is currently pursuing a clinical PhD examining the role comorbidities and social determinants of health in outcomes in inflammatory arthritis.

    Since graduating from the University of Cambridge, in 2016, Mrinalini has pursued a clinical research career focussing on epidemiology, mixed-methods research and outcomes in inflammatory arthritis. Mrinalini sits on the Editorial Board and Digital and Social Media Committee for Rheumatology journal. She the Co-Chair of the Social Media Subcommittee of the Emerging EULAR Network (EMEUNET), as well as sitting on the EULAR People with Arthritis and Rheumatism in Europe (PARE) and Advocacy Committees. Mrinalini has a passion for teaching and science communication, and has previously been a reporter for RheumNow, as well as EULAR TV.

×